Analysis of Prostate Cancer Tumor Microenvironment Identifies Reduced Stromal CD4 Effector T-cell Infiltration in Tumors with Pelvic Nodal Metastasis.pdf
[en] BACKGROUND: Pelvic nodal metastasis in prostate cancer impacts patient outcome negatively. OBJECTIVE: To explore tumor-infiltrating immune cells as a potential predictive tool for regional lymph node (LN) metastasis. DESIGN SETTING AND PARTICIPANTS: We applied multiplex immunofluorescence and targeted transcriptomic analysis on 94 radical prostatectomy specimens in patients with (LN+) or without (LN-) pelvic nodal metastases. Both intraepithelial and stromal infiltrations of immune cells and differentially expressed genes (mRNA and protein levels) were correlated with the nodal status. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The identified CD4 effector cell signature of nodal metastasis was validated in a comparable independent patient cohort of 184 informative cases. Patient outcome analysis and decision curve analysis were performed with the CD4 effector cell density-based signature. RESULTS AND LIMITATIONS: In the discovery cohort, both tumor epithelium and stroma from patients with nodal metastasis had significantly lower infiltration of multiple immune cell types, with stromal CD4 effector cells highlighted as the top candidate marker. Targeted gene expression analysis and confirmatory protein analysis revealed key alteration of extracellular matrix components in tumors with nodal metastasis. Of note, stromal CD4 immune cell density was a significant independent predictor of LN metastasis (odds ratio [OR] = 0.15, p = 0.004), and was further validated as a significant predictor of nodal metastasis in the validation cohort (OR = 0.26, p < 0.001). CONCLUSIONS: Decreased T-cell infiltrates in the primary tumor (particularly CD4 effector cells) are associated with a higher risk of LN metastasis. Future evaluation of CD4-based assays on prostate cancer diagnostic biopsy materials may improve selection of at-risk patients for the treatment of LN metastasis. PATIENT SUMMARY: In this report, we found that cancer showing evidence of cancer metastasis to the lymph nodes tends to have less immune cells present within the tumor. We conclude that the extent of immune cells present within a prostate tumor can help doctors determine the most appropriate treatment plan for individual patients.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Ntala, Chara
Salji, Mark
Salmond, Jonathan
Officer, Leah
Teodosio, Ana Vieira
Blomme, Arnaud ; Université de Liège - ULiège > GIGA Stem Cells - Cancer Signaling
Rawla, P., Epidemiology of prostate cancer. World J Oncol 10 (2019), 63–89.
Angell, H., Galon, J., From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 25 (2013), 261–267.
Galon, J., Mlecnik, B., Bindea, G., et al. Towards the introduction of the’ Immunoscore’ in the classification of malignant tumours. J Pathol 232 (2014), 199–209.
Mezheyeuski, A., Bergsland, C.H., Backman, M., et al. Multispectral imaging for quantitative and compartment-specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients. J Pathol 244 (2018), 421–431.
Carstens, J.L., Correa de Sampaio, P., Yang, D., et al. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun, 8, 2017, 15095.
Brown, J.R., Wimberly, H., Lannin, D.R., Nixon, C., Rimm, D.L., Bossuyt, V., Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 20 (2014), 5995–6005.
Geissler, K., Fornara, P., Lautenschlager, C., Holzhausen, H.J., Seliger, B., Riemann, D., Immune signature of tumor infiltrating immune cells in renal cancer. Oncoimmunology, 4, 2015, e985082.
Fridman, W.H., Pagès, F., Sautès-Fridman, C., Galon, J., The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12 (2012), 298–306.
Huang, W., Hennrick, K., Drew, S., A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays. Hum Pathol 44 (2013), 29–38.
Toth, Z.E., Mezey, E., Simultaneous visualization of multiple antigens with tyramide signal amplification using antibodies from the same species. J Histochem Cytochem 55 (2007), 545–554.
Stack, E.C., Wang, C., Roman, K.A., Hoyt, C.C., Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of tyramide signal amplification, multispectral imaging and multiplex analysis. Methods 70 (2014), 46–58.
Gollapudi, K., Galet, C., Grogan, T., et al. Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. Am J Cancer Res 3 (2013), 523–529.
Cao, J., Liu, J., Xu, R., Zhu, X., Zhao, X., Qian, B.Z., Prognostic role of tumour-associated macrophages and macrophage scavenger receptor 1 in prostate cancer: a systematic review and meta-analysis. Oncotarget 8 (2017), 83261–83269.
Ness, N., Andersen, S., Valkov, A., et al. Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer. Prostate 74 (2014), 1452–1461.
Flammiger, A., Bayer, F., Cirugeda-Kuhnert, A., et al. Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. Acta Pathol Microbiol Immunol Scand 120 (2012), 901–908.
McArdle, P.A., Canna, K., McMillan, D.C., McNicol, A.M., Campbell, R., Underwood, M.A., The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer 91 (2004), 541–543.
Gopalan, A., Leversha, M.A., Satagopan, J.M., et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 69 (2009), 1400–1406.
Demichelis, F., Fall, K., Perner, S., et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26 (2007), 4596–4599.
Lotan, T.L., Gurel, B., Sutcliffe, S., et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 17 (2011), 6563–6573.
Lotan, T.L., Wei, W., Morais, C.L., et al. PTEN loss as determined by clinical-grade immunohistochemistry assay is associated with worse recurrence-free survival in prostate cancer. Eur Urol Focus 2 (2016), 180–188.
Lu, P., Weaver, V.M., Werb, Z., The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 196 (2012), 395–406.
Peranzoni, E., Rivas-Caicedo, A., Bougherara, H., Salmon, H., Donnadieu, E., Positive and negative influence of the matrix architecture on antitumor immune surveillance. Cell Mol Life Sci 70 (2013), 4431–4448.
Briganti, A., Larcher, A., Abdollah, F., et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 61 (2012), 480–487.
Amin, M.B., Edge, S., Greene, F., et al. (eds.) AJCC cancer staging manual, ed. 8, 2017, Springer.
Peng, Z., Skoog, L., Hellborg, H., et al. An expression signature at diagnosis to estimate prostate cancer patients’ overall survival. Prostate Cancer Prostatic Dis 17 (2014), 81–90.
Wakabayashi, O., Yamazaki, K., Oizumi, S., et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 94 (2003), 1003–1009.
Jiang, H., Hegde, S., DeNardo, D.G., Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy. Cancer Immunol Immunother 66 (2017), 1037–1048.
Salmon, H., Franciszkiewicz, K., Damotte, D., et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 122 (2012), 899–910.
Hartmann, N., Giese, N.A., Giese, T., et al. Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer. Clin Cancer Res 20 (2014), 3422–3433.
Bougherara, H., Mansuet-Lupo, A., Alifano, M., et al. Real-time imaging of resident T cells in human lung and ovarian carcinomas reveals how different tumor microenvironments control T lymphocyte migration. Front Immunol, 6, 2015, 500.
Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
